Notwithstanding promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. These https://poppyqblt077454.livebloggs.com/48818935/copyright-s-drug-faces-is-meeting-pbm-obstacles-a-look-of-reimbursement-battles